| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Matrix metalloproteinases (MMPs), specifically MMP-2, -8, -9, and others.
|
|---|---|
| ln Vitro |
Rat brain homogenates treated with p-Aminophenylmercuric acetate (APMA) (0-30 µM; 20 min) exhibit a decrease in the quantity of dihydromorphine binding sites and an increase in agonist sensitivity to sodium binding inhibition [2]. Matrix metalloproteinases 2 and 9 are activated by 0.5 mM; 30 min; p-Aminophenylmercuric acetate [3].
p-Aminophenylmercuric acetate (APMA) is a well-established MMP activator. It participates in the activation and inhibition of MMP-8 by attacking protein sulfhydryl groups or inducing a cysteine conversion reaction. It is used at 0.5 mM to 1.5 mM to activate various metalloproteases. In vitro, APMA (50-100 microM) significantly increases the release of the 26-28kDa BTC extracellular domain in cell lines. |
| ln Vivo |
Currently, no specific in vivo data is available for this compound due to its high toxicity. General information on mercurial compounds indicates they are potent nephrotoxins and neurotoxins, and their use is strictly limited to in vitro experiments.
|
| Enzyme Assay |
A typical in vitro MMP activation protocol involves treating the latent pro-enzyme with 1 mM APMA in a buffer (e.g., 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 10 mM CaCl2) at 37degC for 1-2 hours. The activated MMP can then be used in activity assays with fluorogenic or chromogenic substrates.
|
| Cell Assay |
Latent MMPs (pro-MMPs) are incubated with APMA (0.5-1.5 mM) at 37degC for 1-2 hours. The activation process can be monitored by gelatin zymography, where a shift in molecular weight from the pro-form (higher MW) to the active form (lower MW) is visualized after SDS-PAGE. For cell-based studies, cells are treated with 50-100 microM APMA for 30-60 minutes.
|
| Animal Protocol |
Due to high mercury toxicity, APMA is not used in animal models. For in vitro assays, tissues or cells are homogenized in a lysis buffer, and the protein concentration is quantified. The lysates are incubated with APMA (1 mM) at 37degC for 1 hour to activate MMPs. MMP activity is then measured by adding a fluorogenic substrate.
|
| Toxicity/Toxicokinetics |
APMA is an organic mercury compound and is highly toxic. It is a potent enzyme inhibitor and should be handled with extreme care. Its toxicity arises from its ability to bind to thiol groups in proteins, leading to widespread cellular dysfunction. No clinical data exists; it is strictly for research.
|
| References |
|
| Additional Infomation |
FAD and COA were covalently linked to agarose by chromatography for the purification of FAD and COA.
p-Aminophenylmercuric acetate is a standard research chemical used exclusively for in vitro activation of latent matrix metalloproteinases. It is also known to induce platelet aggregation in a dose-dependent manner and promote beta-cellulose precursor shedding. Its mercury content makes it unsuitable for in vivo applications. |
| Molecular Formula |
C8H9HGNO2
|
|---|---|
| Molecular Weight |
351.75
|
| Exact Mass |
353.034
|
| CAS # |
6283-24-5
|
| PubChem CID |
16682983
|
| Appearance |
White to yellow solid powder
|
| Melting Point |
163-165 °C(lit.)
|
| LogP |
1.035
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
12
|
| Complexity |
155
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC(=O)O[Hg]C1=CC=C(C=C1)N
|
| InChi Key |
RXSUFCOOZSGWSW-UHFFFAOYSA-M
|
| InChi Code |
InChI=1S/C6H6N.C2H4O2.Hg/c7-6-4-2-1-3-5-6;1-2(3)4;/h2-5H,7H2;1H3,(H,3,4);/q;;+1/p-1
|
| Chemical Name |
acetyloxy-(4-aminophenyl)mercury
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 125 mg/mL (355.37 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.91 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (5.91 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8429 mL | 14.2146 mL | 28.4293 mL | |
| 5 mM | 0.5686 mL | 2.8429 mL | 5.6859 mL | |
| 10 mM | 0.2843 mL | 1.4215 mL | 2.8429 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
